CLPT
Clearpoint Neuro Inc
14.60$
-2.4%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 85.1% | 84.8% | 88.3% | 88.6% | 85.4% | 85.1% | 80.5% | 85.9% | 85.0% | 65.1% | 58.7% | 56.2% | |
| 55.5% | 54.2% | 65.9% | 62.5% | 53.7% | 51.3% | 41.2% | 66.1% | 63.3% | 47.0% | 38.1% | 33.9% | |
| 55.5% | 54.2% | 65.9% | 62.5% | 53.7% | 51.3% | 41.2% | 66.1% | 63.3% | 47.0% | 38.1% | 33.9% | |
| 5.5% | 7.5% | 5.8% | 8.6% | 9.6% | 12.0% | 12.1% | 6.8% | 6.6% | 7.4% | 9.3% | 10.8% | |
| 20.5% | 18.5% | 14.8% | 15.3% | 17.6% | 17.5% | 21.9% | 10.0% | 10.9% | 8.6% | 9.2% | 10.2% | |
| – | – | – | – | – | 0.0% | – | – | – | 7.6% | 8.0% | 8.6% | |
| 2.2% | 2.4% | 1.7% | 1.4% | 1.5% | 1.2% | 1.9% | – | – | 14.2% | 14.4% | 14.9% | |
| 45.0% | 50.4% | 35.5% | 38.9% | 27.8% | 35.2% | 33.5% | 68.6% | 73.7% | 71.3% | 79.8% | 87.6% | |
| 12.7% | 17.4% | 28.3% | 31.8% | 18.8% | 26.4% | 22.8% | 11.8% | 13.3% | 11.0% | 10.1% | 11.9% | |
| 0.9% | 1.0% | 19.5% | 20.0% | 1.3% | 1.4% | 1.9% | 0.5% | 0.6% | 0.7% | 0.3% | 0.2% | |
| 1.8% | 0.9% | 1.6% | 1.6% | 2.4% | 3.4% | 4.0% | 2.4% | 1.2% | 1.3% | 2.5% | 2.5% | |
| 22.7% | 23.3% | – | – | – | – | – | 45.9% | 48.4% | 50.2% | 53.1% | 57.9% | |
| 55.0% | 49.6% | 64.5% | 61.1% | 72.2% | 64.8% | 66.5% | 31.4% | 26.3% | 28.7% | 20.2% | 12.4% | |
| -382.9% | -404.2% | -329.3% | -344.3% | -462.7% | -488.3% | -656.5% | -323.3% | -346.5% | -221.9% | -242.4% | -274.1% | |
| 56.2% | 57.7% | 47.5% | 52.2% | 68.6% | 69.0% | 92.2% | 44.9% | 47.1% | 29.0% | 31.6% | 34.4% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.